US FDA Envisions Advisory Committees For Allergy, Asthma Biomarkers With ‘Real Impact’

 
• By Sarah Karlin-Smith

Expert panels may be used to help the FDA decide when and how a new biomarker could be leveraged for regulatory purposes. Participants at workshop on allergy and asthma biomarkers also discuss need for standardization of food allergy trials and new trial design approaches. 

blurred image of people meeting around a oval shaped table
Advisory committees may help FDA decide the utility of biomarkers for allergy and asthma drug development programs • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers